Reckitt Benckiser Group (RB) PT Raised to GBX 7,450 at Berenberg Bank

Reckitt Benckiser Group (LON:RB) had its target price hoisted by equities researchers at Berenberg Bank from GBX 7,300 ($95.39) to GBX 7,450 ($97.35) in a report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 19.10% from the stock’s current price.

Several other equities analysts also recently issued reports on RB. Liberum Capital restated a “buy” rating and set a GBX 7,400 ($96.69) price objective on shares of Reckitt Benckiser Group in a report on Tuesday, July 24th. JPMorgan Chase & Co. set a GBX 7,000 ($91.47) price objective on shares of Reckitt Benckiser Group and gave the company a “buy” rating in a report on Monday, July 23rd. Cfra set a GBX 7,500 ($98.00) price objective on shares of Reckitt Benckiser Group and gave the company a “buy” rating in a report on Monday, July 30th. Citigroup restated a “buy” rating and set a GBX 7,650 ($99.96) price objective (up previously from GBX 7,200 ($94.08)) on shares of Reckitt Benckiser Group in a report on Thursday, August 30th. Finally, Sanford C. Bernstein set a GBX 8,200 ($107.15) price objective on shares of Reckitt Benckiser Group and gave the company a “buy” rating in a report on Thursday, October 4th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of GBX 7,007.37 ($91.56).

Shares of RB stock traded down GBX 9 ($0.12) during mid-day trading on Thursday, hitting GBX 6,255 ($81.73). 1,462,775 shares of the stock traded hands, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 52-week low of GBX 5,562 ($72.68) and a 52-week high of GBX 8,110.43 ($105.98).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: Earnings Per Share

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply